12:12 PM EDT, 06/25/2024 (MT Newswires) -- ImmunoPrecise Antibodies ( IPA ) said Tuesday its BioStrand unit is partnering with PGxAI to create an adaptive artificial intelligence model to predict patient responses to drugs, transforming personalized medicine.

Financial details of the partnership weren't disclosed.

PGxAI will utilize BioStrand's foundation AI model LENSai to develop an AI model for pharmacogenomics, the study of how genetic variations affect drug response, ImmunoPrecise said.

Shares of ImmunoPrecise were up 3% in recent trading.

Price: 1.03, Change: +0.03, Percent Change: +3.00